CD274 and neoplasm: On the other hand, preclinical data have shown potent anti-tumor activity with the blockade of the PD-1/PD-L1 and HER2 pathways, as well as a bridging effect between T cells and tumor cells, with the first-in-class anti-HER2/PD-1 bispecific antibody IBI315.